The last decade has witnessed significant progress in the understanding of the immune system and led to the development of immune checkpoints blockades such as anti-CTLA-4, anti-PD-1 and anti-PD-L1, which has shown the potential to bring a paradigm shift in management and prognosis of several cancers, including liver cancer [55,65]. This evidence concerns the gene PDCD1 and cancer.